United States ban on blood donation by gay community off

The Food and Drug Administration said its decision to reverse the policy was based on an examination of the latest science which shows that an indefinite ban is not necessary to prevent transmission of HIV, the virus that causes AIDS. “Ultimately, the 12-month deferral window is supported by the best available scientific evidence, at this point in time, relevant to the U.S. population,” Dr. Peter Marks, deputy director of the FDA’s biologics division, said in a statement.

The move brings the United States in line with countries such as the United Kingdom, Australia and New Zealand which also have 12-month deferral periods. Gay rights advocates said the updated policy remains discriminatory. “It is ridiculous and counter to the public health that a married gay man in a monogamous relationship can’t give blood, but a promiscuous straight man who has had hundreds of opposite sex partners in the last year can,” said Jared Polis, a Democratic congressman and co-chair of the Congressional LGBT Equality Caucus, a caucus of openly gay members of Congress. 

The FDA said it has worked with other government agencies and considered input from outside advisory bodies, and has “carefully examined the most recent available scientific evidence to support the current policy revision.” During Australia’s switch from an indefinite blood donor deferral policy on gay men, essentially a ban, to a 12-month deferral, studies evaluating more than 8 million units of donated blood were performed using a national blood surveillance system, the FDA said. “These published studies document no change in risk to the blood supply with use of the 12-month deferral,” the agency said. “Similar data is not available for shorter deferral intervals.” 

The agency said it has put in place a safety monitoring system for the blood supply which it expects to provide “critical information” to help inform future FDA blood donor policies. The FDA said its policies have helped reduce HIV transmission rates from blood transfusions from 1 in 2,500 to 1 in 1.47 million. The FDA first proposed the changes in May. It received some 700 public comments. About half recommended keeping the ban in place.